Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 2/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 15/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 12/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 8/20 | 0.51 |
| ▸ | PIK3C3 | Q8NEB9 | 4/20 | 0.42 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.42 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.40 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3758081 | 0.89 | PRKDC (0.59) | PRKDCPIK3CGPIK3CAPIK3CD | |
| SCHEMBL3754528 | 0.87 | PRKDC (0.57) | PRKDCPIK3CGPIK3CA | |
| SCHEMBL3757850 | 0.85 | PRKDC (0.52) | PRKDCPIK3CA | |
| SCHEMBL3756362 | 0.84 | PRKDC (0.57) | PRKDCPIK3CA | |
| SCHEMBL3749833 | 0.83 | PRKDC (0.56) | PRKDCPIK3CA | |
| SCHEMBL3754238 | 0.83 | PRKDC (0.56) | PRKDCPIK3CA | |
| SCHEMBL3755774 | 0.81 | PIK3CA (0.54) | PRKDCPIK3CA | |
| SCHEMBL3754519 | 0.81 | PRKDC (0.62) | PRKDCPIK3CA | |
| SCHEMBL3752813 | 0.81 | PRKDC (0.53) | PRKDCPIK3CA | |
| SCHEMBL7869191 | 0.81 | PRKDC (0.56) | PRKDCPIK3CGPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | PRKDC 480/4885PIK3CG 47/4885PIK3CA 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.